July 21, 2017 10:16 AM ET


Company Overview of Fidia Farmaceutici s.p.a.

Company Overview

Fidia Farmaceutici s.p.a. engages in the research and development, production, and sale of medicinal products, medical devices, and nutritional supplements in Europe, North America, Latin America, the Middle East, and Far East. The company’s product portfolio focuses primarily on therapeutic areas, including joint healthcare; tissue repair and dermatology; a line of health and wellness products in women's hygiene; and central nervous system pathologies. It also offers viscosupplementation that includes products primarily based on hyaluronic acid and its derivatives for the treatment of joint healthcare, advanced wound care, dermatology, neurology, and dermo-aesthetics problems; and branded p...

Via Ponte della Fabbrica 3/A

Abano Terme, PD 35031


Founded in 1946


39 04 98 23 21 11


39 04 49 81 06 53

Key Executives for Fidia Farmaceutici s.p.a.

Chief Executive Officer
Compensation as of Fiscal Year 2017.

Fidia Farmaceutici s.p.a. Key Developments

Fidia Farmaceutici S.p.A. Introduces Hymovi

Fidia Farmaceutici S.p.A. will introduce Hymovis (high molecular weight viscoelastic hyaluronan) at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) in Orlando, March 1, to March 5, 2016. Hymovis is a next-generation of HA-based intra-articular (IA) therapy indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics. The product has a shorter treatment cycle of only two intra-articular injections as compared to many other IA HA viscosupplement regimens to provide pain relief for the patient. Scientists from Fidia Farmaceutici S.p.A. and the research group led by Dr. Lawrence Bonassar, Professor in the Meinig School of Biomedical Engineering at Cornell University worked together to verify the optimal lubricating characteristics of the HA derivative. Hymovis was bioengineered using a proprietary process that results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints. The formulation allows the molecule to recover its original structure, even after repetitive mechanical stress. Due to reversible hydrophobic interactions, the non-crosslinked Hymovis has increased elasticity, viscosity and residence time in the joint.

Similar Private Companies By Industry

Company Name Region
A. Menarini Industrie Farmaceutiche Riunite Srl Europe
Aboca S.p.A. - Societa Agricola Europe
ACME S.r.l. Europe
Acs Dobfar spa Europe
Agrisana S.R.L. Europe

Recent Private Companies Transactions

February 28, 2017
SOOFT Italia S.p.a.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fidia Farmaceutici s.p.a., please visit www.fidiapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.